Ramipril 10 mg Capsule in Healthy Subjects Under Fasting Conditions

This study has been completed.

Sponsor:

Information provided by:

Teva Pharmaceuticals USA

ClinicalTrials.gov Identifier:

NCT00829452

First received: January 23, 2009

Last updated: September 1, 2009

Last verified: September 2009

History of Changes

Results First Received: July 2, 2009

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Bio-equivalence Study; Intervention Model: Crossover Assignment; Masking: Open Label
Condition:	Healthy
Interventions:	Drug: Ramipril 10 mg capsule Drug: Altace® 10 mg capsule

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Test (Ramipril) First	10 mg Ramipril Capsules test product dosed in first period followed by 10 mg Altace® Capsules reference product dosed in the second period.
Reference (Altace®) First	10 mg Altace® Capsules reference product dosed in first period followed by 10 mg Ramipril Capsules test product dosed in the second period.

Participant Flow for 3 periods

Period 1: First Intervention

	Test (Ramipril) First	Reference (Altace®) First
STARTED	20	20
COMPLETED	20	19
NOT COMPLETED	0	1
Withdrawal by Subject	0	1

Period 2: Washout of 42 Days

	Test (Ramipril) First	Reference (Altace®) First
STARTED	20	19
COMPLETED	20	18
NOT COMPLETED	0	1
Withdrawal by Subject	0	1

Period 3: Second Intervention

	Test (Ramipril) First	Reference (Altace®) First
STARTED	20	18
COMPLETED	20	17
NOT COMPLETED	0	1
Physician Decision	0	1

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Test (Ramipril) First	10 mg Ramipril Capsules test product dosed in first period followed by 10 mg Altace® Capsules reference product dosed in the second period.
Reference (Altace®) First	10 mg Altace® Capsules reference product dosed in first period followed by 10 mg Ramipril Capsules test product dosed in the second period.
Total	Total of all reporting groups

Baseline Measures

	Test (Ramipril) First	Reference (Altace®) First	Total
Number of Participants [units: participants]	20	20	40
Age [units: participants]
<=18 years	0	0	0
Between 18 and 65 years	19	20	39
>=65 years	1	0	1
Gender [units: participants]
Female	12	12	24
Male	8	8	16
Race/Ethnicity, Customized [units: participants]
Asian	0	1	1
Black	0	2	2
White	18	13	31
Hispanic	2	4	6
Region of Enrollment [units: participants]
Canada	20	20	40

Outcome Measures

Show All Outcome Measures

1. Primary:

Cmax (Maximum Observed Concentration of Drug Substance in Plasma)for Ramipril. [ Time Frame: Blood samples collected over a 72 hour period. ]

Show Outcome Measure 1

2. Primary:

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) for Ramipril. [ Time Frame: Blood samples collected over a 72 hour period. ]

Hide Outcome Measure 2

Measure Type	Primary
Measure Title	AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) for Ramipril.
Measure Description	Bioequivalence based on AUC0-t.
Time Frame	Blood samples collected over a 72 hour period.
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
All participants that completed the study had their samples analyzed.

Reporting Groups

	Description
Test (Ramipril)	10 mg Ramipril Capsules test product dosed in either period.
Reference (Altace®)	10 mg Altace® Capsules reference product dosed in either period.

Measured Values

	Test (Ramipril)	Reference (Altace®)
Number of Participants Analyzed [units: participants]	37	37
AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) for Ramipril. [units: pg*h/mL] Mean ± Standard Deviation	17495.08 ± 5964.21	18487.79 ± 6792.41

Statistical Analysis 1 for AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration) for Ramipril.

Groups ^[1]	All groups
Non-Inferiority/Equivalence Test ^[2]	Yes
Ratio of the T/R geometric mean x 100 ^[3]	95.34
90% Confidence Interval	( 90.82 to 100.09 )

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	No text entered.
[2]	Details of power calculation, definition of non-inferiority margin, and other key parameters:
	The ANOVA model was utilized in comparing the effects between the test and reference products. Differences were declared statistically significant at the 5% level (p<0.05).
[3]	Other relevant estimation information:
	Bioequivalence is established if the 90% confidence interval for the ln-transformed geometric mean between the reference and test product fall within the interval of 80-125%.

3. Primary:

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity) for Ramipril. [ Time Frame: Blood samples collected over a 72 hour period. ]

Show Outcome Measure 3

4. Secondary:

Cmax (Maximum Observed Concentration of Drug Substance in Plasma)for Ramiprilat. [ Time Frame: Blood samples collected over a 72 hour period. ]

Show Outcome Measure 4

5. Secondary:

AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time of 72 Hours) for Ramiprilat. [ Time Frame: Blood samples collected over a 72 hour period. ]

Show Outcome Measure 5

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: The Principal Investigator is not permitted to discuss or publish trial results.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Manager, Biopharmaceutics
Organization: TEVA Pharmaceuticals, USA
phone: 1-866-384-5525
e-mail: clinicaltrialqueries@tevausa.com

No publications provided

ClinicalTrials.gov Identifier:	NCT00829452 History of Changes
Other Study ID Numbers:	40181
Study First Received:	January 23, 2009
Results First Received:	July 2, 2009
Last Updated:	September 1, 2009
Health Authority:	United States: Institutional Review Board

To Top